Insmed

News

Insmed partners patient group on bronchiectasis study

Insmed is working with a bronchiectasis patient organisation on a real-world trial of Brinsupri, the first FDA-approved drug for the lung disorder.

News

Infex chases after Insmed with bronchiectasis trial win

UK biotech Infex is in hot pursuit of Insmed's Brinsupri, the only approved therapy for non-CF bronchiectasis, with its quarterly-dosed antibody.

News

CHMP backs first drug for lung disease bronchiectasis

Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, plus other CHMP decisions.

News

Insmed gets first FDA approval for bronchiectasis

Insmed has claimed the distinction of getting the first FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis.

News

Insmed's chief medical officer Martina Flammer

FDA starts review of first bronchiectasis drug candidate

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for bronchiectasis in the US.

News

Trial readout sets up filings for Insmed bronchiectasis drug

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis

Insmed

Editor's Picks